Literature DB >> 2586021

[Type I oxalosis in childhood--studies within the scope of terminal renal failure in the child].

M Frosch1, E Kuwertz-Bröking, M Bulla, D B von Bassewitz, D B Leusmann.   

Abstract

The difficulties of biochemical diagnosis in children and in chronic renal failure are discussed in detail, as well as the development of diagnostic and therapeutic possibilities in recent years, exemplified by 4 cases. Excretion of oxalate (and glycolate) may be incorrectly assumed to be normal with: a) uncritical application of the method of measurement, b) disregard of the clearly lower oxalate excretion in children (values should be referred to m2 of body surface), c) disregard of a decreased glomerular filtration rate (values should be referred to the creatinine clearance). With compromised renal function the excretion of oxalate and glycolate in primary oxalosis drops to "normal" whereas plasma values increase considerably. In this case the biochemical diagnosis is possible only by measurement of plasma values of glycolate and oxalate. Consequently, extensive extrarenal deposition of calcium oxalate crystals will, as a rule, become clinically manifest only after chronic renal failure has turned irreversible. In recent years, several therapeutic procedures, have been developed. They are of therapeutic significance for the early stages of the disease as well. Observing especially conditions renal transplantation or combined hepatorenal transplantation can be managed with a successful outcome. As the perioxisomal enzyme is activated only in the liver cells, an early liver transplantation as a definitive treatment by enzyme replacement may be the successful therapy in the future.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2586021     DOI: 10.1007/bf01726118

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  87 in total

1.  THE METABOLIC DEFECT OF PRIMARY HYPEROXALURIA.

Authors:  L H SMITH; T D HOCKADAY; M L EFRON; J E CLAYTON
Journal:  Trans Assoc Am Physicians       Date:  1964

2.  Renal transplantation in primary hyperoxaluria.

Authors:  A Saxon; G J Busch; J P Merrill; V Franco; R E Wilson
Journal:  Arch Intern Med       Date:  1974-03

3.  A simplified and rapid enzymatic method for determination of urinary oxalate.

Authors:  P C Hallson; G A Rose
Journal:  Clin Chim Acta       Date:  1974-08-30       Impact factor: 3.786

4.  The action of pyridoxine in primary hyperoxaluria.

Authors:  D A Gibbs; R W Watts
Journal:  Clin Sci       Date:  1970-02       Impact factor: 6.124

5.  Treatment of primary hyperoxaluria.

Authors:  C E Dent; T C Stamp
Journal:  Arch Dis Child       Date:  1970-12       Impact factor: 3.791

6.  Combined report on regular dialysis and transplantation in Europe, XI, 1980.

Authors:  C Jacobs; M Broyer; F P Brunner; H Brynger; R A Donckerwolcke; P Kramer; N H Selwood; A J Wing; P H Blake
Journal:  Proc Eur Dial Transplant Assoc       Date:  1981

7.  Studies on some possible biochemical treatments of primary hyperoxaluria.

Authors:  R W Watts; R A Chalmers; D A Gibbs; A M Lawson; P Purkiss; E Spellacy
Journal:  Q J Med       Date:  1979-04

8.  Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation.

Authors:  R W Watts; R Y Calne; R Williams; M A Mansell; N Veall; P Purkiss; K Rolles
Journal:  Q J Med       Date:  1985-10

9.  Successful renal transplantation in primary hyperoxaluria.

Authors:  P O'Regan; A R Constable; A M Joekes; G P Kasidas; G A Rose
Journal:  Postgrad Med J       Date:  1980-04       Impact factor: 2.401

Review 10.  Perspectives in the assessment and management of patients with primary hyperoxaluria type I.

Authors:  S H Morgan; R W Watts
Journal:  Adv Nephrol Necker Hosp       Date:  1989
View more
  1 in total

1.  Excessive urinary oxalate excretion after combined renal and hepatic transplantation for correction of hyperoxaluria type 1.

Authors:  H Ruder; G Otto; R B Schutgens; U Querfeld; R J Wanders; K H Herzog; P Wölfel; S Pomer; K Schärer; G A Rose
Journal:  Eur J Pediatr       Date:  1990-11       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.